Our future is shaped by innovation

Commitment to innovation is a central pillar of Dexcel’s culture. We devote resources to bring new pharmaceutical drugs to market and address patient needs. Our commitment to development and innovation in biopharmaceuticals spans therapeutic areas and modalities. We advance small molecules, siRNA, and biologics while also developing cost-effective generics

Development of complex generics and unique formulations

Dexcel Pharma utilizes in-house formulation know-how and drug delivery technologies to develop complex generic formulations and introduce unique product presentations. We leverage our regulatory expertise to enable new product development and identify niche product opportunities

Dexcel Pharma makes significant investments to support long-term growth and innovation
dexoligo logo

Commitment to innovation
in RNA

Dexcel formed Dexoligo with the mission to translate the revolution of RNA therapeutics into novel medicines. Dexoligo is building an in-house pipeline of innovative medicines focused on siRNA therapeutics, oligonucleotides, and delivery solutions, to address areas of major unmet medical needs. Dexoligo focuses on areas of high unmet need where the use of siRNA therapeutics could be transformational

Dexoligo Therapeutics
blue arrow points to the right
clexio logo

Novel Therapies in Neurology & Psychiatry

Dexcel formed Clexio Biosciences to bring innovative medicine for neurological and psychiatric conditions to significant unmet needs. Clexio is a multi-asset, CNS-first clinical-stage pharmaceutical company with a broad and growing pipeline

Clexio Biosciences
blue arrow points to the right
blue bubbles
roivant logo

Reinventing the discovery and development of new medicines

In 2014, Dexcel became the founding investor of Roivant Sciences, with an aim to take an active part in developing new and highly innovative medicines. Roivant Sciences is a unique biopharmaceutical firm dedicated to realizing the full value of promising drug candidates by advancing them from late-stage clinical development to commercialization

Roivant Sciences
blue arrow points to the right